Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 ...

Valneva (NASDAQ:VALN – Free Report) had its target price trimmed by HC Wainwright from $18.00 to $17.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...

Shares of Valneva (NASDAQ:VALN ... Healthcare Products Regulatory Agency granted marketing authorization for its chikungunya vaccine. Accordingly, the single-shot vaccine branded as Ixchiq ...

Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults.